? CORE 1 The Viral Vector Core (Core 1) will provide customized lentiviral or retroviral vectors to all PPG projects. Lentiviral or retroviral vector particles are fundamental reagents necessary for the efficient genetic engineering of HTLV-1 infected cells. The vector particles will be used to overexpress or reduce expression of host, viral, or novel fusion genes. Reduced expression will be achieved by delivery of either shRNA or CRISPR/Cas9. The vectors for reduced expression will be matched with vectors for complementation with wild type and functional mutant genes with silent mutations to prevent shRNA or CRISPR recognition. Lentiviral vector particles will also provide fluorescent and/or selection genes. Homology directed repair induced by a CRISPR/Cas9 vector will modify the HTLV-1 genome sequence. Integrase defective lentiviral vectors will be used to quantify the off- target effects of all CRISPR/Cas9 vectors. The Core will work with individual PPG labs to develop CRISPR/Cas9 reagents and methodologies for modification of HTLV-1 infected cells. The Core will also develop a novel vector that limits Cas9 expression both spatially and temporally to transcriptionally active HTLV-1 infected cells and reduce potential off-target editing.
Specific aims of the core are:
Aim 1 to provide custom retroviral vectors, Aim 2 to design, validate, and optimize CRISPR/Cas9 vectors, Aim 3 to develop an inducible, self-limiting HTLV-1 CRISPR/Cas9 vector. The lentiviral or retroviral vector particles produced by the Core will service Projects 1-3 of this PPG.

Public Health Relevance

? CORE 1 The Viral Vector Core will provide custom high quality lentiviral or retroviral vector particles to PPG labs for overexpression or reduced expression of host, viral, or novel function genes. Reduced expression vectors will deliver either shRNA or CRISPR/Cas9 to cells. Finally, a novel lentiviral CRISPR/Cas9 vector will be developed to limit Cas9 expression spatially and temporally.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Murali, Bhavna; Ren, Qihao; Luo, Xianmin et al. (2018) Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss. Cancer Res 78:5618-5630
Huey, Devra D; Niewiesk, Stefan (2018) Production of Humanized Mice through Stem Cell Transfer. Curr Protoc Mouse Biol 8:17-27
Romeo, Megan; Hutchison, Tetiana; Malu, Aditi et al. (2018) The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis. Virology 518:103-115
Cherian, Mathew A; Olson, Sydney; Sundaramoorthi, Hemalatha et al. (2018) An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem 293:6844-6858
Huey, Devra D; Bolon, Brad; La Perle, Krista M D et al. (2018) Role of Wild-type and Recombinant Human T-cell Leukemia Viruses in Lymphoproliferative Disease in Humanized NSG Mice. Comp Med 68:4-14
Pérès, Eléonore; Blin, Juliana; Ricci, Emiliano P et al. (2018) PDZ domain-binding motif of Tax sustains T-cell proliferation in HTLV-1-infected humanized mice. PLoS Pathog 14:e1006933
Panfil, Amanda R; Al-Saleem, Jacob; Howard, Cory M et al. (2018) Stability of the HTLV-1 Antisense-Derived Protein, HBZ, Is Regulated by the E3 Ubiquitin-Protein Ligase, UBR5. Front Microbiol 9:80
Webb, Lindsay M; Amici, Stephanie A; Jablonski, Kyle A et al. (2017) PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis. J Immunol 198:1439-1451
Singh, Gatikrushna; Fritz, Sarah M; Ranji, Arnaz et al. (2017) Isolation of Cognate RNA-protein Complexes from Cells Using Oligonucleotide-directed Elution. J Vis Exp :
Ross, Michael H; Esser, Alison K; Fox, Gregory C et al. (2017) Bone-Induced Expression of Integrin ?3 Enables Targeted Nanotherapy of Breast Cancer Metastases. Cancer Res 77:6299-6312

Showing the most recent 10 out of 162 publications